GSK completes divestment of thrombosis brands and related manufacturing site to Aspen

GlaxoSmithKline (“GSK”) today completed the previously announced divestment of its thrombosis brands, ArixtraTM and FraxiparineTM to the Aspen Group (Aspen) for £700 million.
Source: GSK news - Category: Pharmaceuticals Source Type: news